B-013

N/A

Report date: 2025/03/03 16:44:56

Base Information

Drug NameB-013
Drug Alias NameB013B-013
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Crosslink Pharmaceutical R & D Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Pharmaceuticals Holding Co LtdShanghai Crosslink Pharmaceutical R & D Co Ltd
Inactive CompaniesN/A
Active IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsTriple Negative Breast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A